• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

喷雾干燥法和冷冻干燥法在缬沙坦固体自微乳制剂中的应用比较及体外和体内评价。

A comparison between use of spray and freeze drying techniques for preparation of solid self-microemulsifying formulation of valsartan and in vitro and in vivo evaluation.

机构信息

Department of Pharmaceutics, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India.

出版信息

Biomed Res Int. 2013;2013:909045. doi: 10.1155/2013/909045. Epub 2013 Jul 18.

DOI:10.1155/2013/909045
PMID:23971048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3732638/
Abstract

The objective of the present study was to develop self micro emulsifying formulation (SMEF) of valsartan to improve its oral bioavailability. The formulations were screened on the basis of solubility, stability, emulsification efficiency, particle size and zeta potential. The optimized liquid SMEF contains valsartan (20% w/w), Capmul MCM C8 (16% w/w), Tween 80 (42.66% w/w) and PEG 400 (21.33% w/w) as drug, oil, surfactant and co-surfactant, respectively. Further, Liquid SMEF was adsorbed on Aerosol 200 by spray and freeze drying methods in the ratio of 2 : 1 and transformed into free flowing powder. Both the optimized liquid and solid SMEF had the particle size <200 nm with rapid reconstitution properties. Both drying methods are equally capable for producing stable solid SMEF and immediate release of drug in in vitro and in vivo conditions. However, the solid SMEF produced by spray drying method showed high flowability and compressibility. The solid state characterization employing the FTIR, DSC and XRD studies indicated insignificant interaction of drug with lipid and adsorbed excipient. The relative bioavailability of solid SMEF was approximately 1.5 to 3.0 folds higher than marketed formulation and pure drug. Thus, the developed solid SMEF illustrates an alternative delivery of valsartan as compared to existing formulations with improved bioavailability.

摘要

本研究旨在开发缬沙坦自微乳制剂 (SMEF) 以提高其口服生物利用度。根据溶解度、稳定性、乳化效率、粒径和zeta 电位对制剂进行筛选。优化的液体 SMEF 含有缬沙坦(20%w/w)、Capmul MCM C8(16%w/w)、吐温 80(42.66%w/w)和 PEG 400(21.33%w/w),分别作为药物、油相、表面活性剂和助表面活性剂。进一步,将液体 SMEF 以 2:1 的比例通过喷雾和冷冻干燥吸附到 Aerosol 200 上,并转化为自由流动的粉末。优化后的液体和固体 SMEF 的粒径均<200nm,具有快速再构成特性。两种干燥方法都能够生产出稳定的固体 SMEF,并在体外和体内条件下实现药物的即刻释放。然而,喷雾干燥法制备的固体 SMEF 表现出高流动性和可压缩性。采用傅里叶变换红外光谱 (FTIR)、差示扫描量热法 (DSC) 和 X 射线衍射 (XRD) 研究的固态特性表明,药物与脂质和吸附赋形剂之间没有明显的相互作用。与市售制剂和纯药物相比,固体 SMEF 的相对生物利用度约提高 1.5 至 3.0 倍。因此,与现有制剂相比,开发的固体 SMEF 说明了缬沙坦的替代给药方式,具有改善的生物利用度。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/3029fb20ec99/BMRI2013-909045.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/7519c46a3797/BMRI2013-909045.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/343d3ed27351/BMRI2013-909045.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/7e360e3e0544/BMRI2013-909045.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/243f05cc1f84/BMRI2013-909045.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/41e808bf1f58/BMRI2013-909045.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/b7b2a8f63d68/BMRI2013-909045.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/b67842a63a7e/BMRI2013-909045.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/5bb8ac05646e/BMRI2013-909045.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/eb731944e007/BMRI2013-909045.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/3029fb20ec99/BMRI2013-909045.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/7519c46a3797/BMRI2013-909045.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/343d3ed27351/BMRI2013-909045.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/7e360e3e0544/BMRI2013-909045.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/243f05cc1f84/BMRI2013-909045.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/41e808bf1f58/BMRI2013-909045.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/b7b2a8f63d68/BMRI2013-909045.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/b67842a63a7e/BMRI2013-909045.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/5bb8ac05646e/BMRI2013-909045.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/eb731944e007/BMRI2013-909045.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e491/3732638/3029fb20ec99/BMRI2013-909045.010.jpg

相似文献

1
A comparison between use of spray and freeze drying techniques for preparation of solid self-microemulsifying formulation of valsartan and in vitro and in vivo evaluation.喷雾干燥法和冷冻干燥法在缬沙坦固体自微乳制剂中的应用比较及体外和体内评价。
Biomed Res Int. 2013;2013:909045. doi: 10.1155/2013/909045. Epub 2013 Jul 18.
2
Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers.采用多孔载体制备缬沙坦固体自微乳给药系统的开发、优化和特性研究。
AAPS PharmSciTech. 2012 Dec;13(4):1416-27. doi: 10.1208/s12249-012-9865-5. Epub 2012 Oct 16.
3
Formulation, characterization and optimization of valsartan self-microemulsifying drug delivery system using statistical design of experiment.使用实验统计设计对缬沙坦自微乳化药物递送系统进行制剂、表征及优化
Chem Pharm Bull (Tokyo). 2012;60(11):1409-18. doi: 10.1248/cpb.c12-00502.
4
Novel valsartan-loaded solid dispersion with enhanced bioavailability and no crystalline changes.新型缬沙坦固体分散体,生物利用度提高,无晶体变化。
Int J Pharm. 2012 Jan 17;422(1-2):202-10. doi: 10.1016/j.ijpharm.2011.10.053. Epub 2011 Nov 6.
5
Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.采用羟丙甲纤维素作为稳定剂制备载缬沙坦明胶微胶囊且无晶体变化。
Drug Deliv. 2010 Jul;17(5):322-9. doi: 10.3109/10717541003717031.
6
Pharmacokinetic Evaluation of Improved Oral Bioavailability of Valsartan: Proliposomes Versus Self-Nanoemulsifying Drug Delivery System.缬沙坦口服生物利用度改善的药代动力学评价:前体脂质体与自纳米乳化药物递送系统的比较
AAPS PharmSciTech. 2016 Aug;17(4):851-62. doi: 10.1208/s12249-015-0388-8. Epub 2015 Sep 17.
7
Uniform nano-sized valsartan for dissolution and bioavailability enhancement: influence of particle size and crystalline state.均一纳米尺寸缬沙坦提高药物溶解和生物利用度:粒径和晶体状态的影响。
Int J Pharm. 2013 Jan 30;441(1-2):75-81. doi: 10.1016/j.ijpharm.2012.12.025. Epub 2012 Dec 21.
8
Preparation and bioavailability assessment of SMEDDS containing valsartan.含缬沙坦的 SMEDDS 的制备及生物利用度评价。
AAPS PharmSciTech. 2010 Mar;11(1):314-21. doi: 10.1208/s12249-010-9385-0. Epub 2010 Feb 25.
9
Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion.通过制备固体分散体提高缬沙坦的 pH 不依赖性溶出度和口服吸收。
Arch Pharm Res. 2010 Aug;33(8):1235-40. doi: 10.1007/s12272-010-0814-0. Epub 2010 Aug 28.
10
Fabrication and evaluation of valsartan-polymer- surfactant composite nanoparticles by using the supercritical antisolvent process.采用超临界抗溶剂法制备缬沙坦-聚合物-表面活性剂复合纳米粒及其评价
Int J Nanomedicine. 2014 Nov 7;9:5167-76. doi: 10.2147/IJN.S71891. eCollection 2014.

引用本文的文献

1
Development of Rapidly Dissolving Microneedles Integrated with Valsartan-Loaded Nanoliposomes for Transdermal Drug Delivery: In Vitro and Ex Vivo Evaluation.用于透皮给药的载缬沙坦纳米脂质体快速溶解微针的研制:体外和离体评价
Pharmaceutics. 2025 Apr 7;17(4):483. doi: 10.3390/pharmaceutics17040483.
2
Anticancer Potential of Pineapple and its Bioactive Compound Bromelain.菠萝及其生物活性化合物菠萝蛋白酶的抗癌潜力
Curr Pharm Des. 2025;31(6):461-483. doi: 10.2174/0113816128303910240713180835.
3
Design and physico-mechanical evaluation of fast-dissolving valsartan polymeric drug delivery system by electrospinning method.

本文引用的文献

1
Pioglitazone solid dispersion system prepared by spray drying method: in vitro and in vivo evaluation.喷雾干燥法制备的吡格列酮固体分散体系统:体内外评价
PDA J Pharm Sci Technol. 2013 Jan-Feb;67(1):23-34. doi: 10.5731/pdajpst.2013.00899.
2
Efficacy and toxicological studies of cremophor EL free alternative paclitaxel formulation.无聚氧乙烯蓖麻油的替代紫杉醇制剂的疗效和毒理学研究
Curr Drug Saf. 2011 Nov 1;6(5):329-38. doi: 10.2174/157488611798918764.
3
Studies on binary lipid matrix based solid lipid nanoparticles of repaglinide: in vitro and in vivo evaluation.
通过静电纺丝法制备快速溶解缬沙坦聚合物药物递送系统的设计与物理力学评估
Iran J Basic Med Sci. 2021 Dec;24(12):1683-1694. doi: 10.22038/IJBMS.2021.58713.13041.
4
Solidification of Self-Emulsifying Drug Delivery Systems as a Novel Approach to the Management of Uncomplicated Malaria.自乳化药物递送系统的固化作为一种治疗非复杂性疟疾的新方法。
Pharmaceuticals (Basel). 2022 Jan 20;15(2):120. doi: 10.3390/ph15020120.
5
3D Printing of Dapagliflozin Containing Self-Nanoemulsifying Tablets: Formulation Design and In Vitro Characterization.含达格列净自纳米乳化片的3D打印:处方设计与体外表征
Pharmaceutics. 2021 Jun 30;13(7):993. doi: 10.3390/pharmaceutics13070993.
6
Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems.过饱和自乳化药物递送系统的现状
Pharmaceutics. 2020 Apr 16;12(4):365. doi: 10.3390/pharmaceutics12040365.
7
MOF Capacitates Cyclodextrin to Mega-Load Mode for High-Efficient Delivery of Valsartan.MOF 使环糊精处于超大装载模式,以实现缬沙坦的高效传递。
Pharm Res. 2019 Jun 3;36(8):117. doi: 10.1007/s11095-019-2650-3.
8
Inclusion of Digestible Surfactants in Solid SMEDDS Formulation Removes Lag Time and Influences the Formation of Structured Particles During Digestion.在固体自微乳化药物传递系统(SMEDDS)制剂中加入可消化表面活性剂可消除滞后时间,并影响消化过程中结构化颗粒的形成。
AAPS J. 2017 May;19(3):754-764. doi: 10.1208/s12248-016-0036-6. Epub 2017 Jan 23.
9
Soluplus®/TPGS-based solid dispersions prepared by hot-melt extrusion equipped with twin-screw systems for enhancing oral bioavailability of valsartan.采用配备双螺杆系统的热熔挤出法制备的基于Soluplus®/TPGS的固体分散体,用于提高缬沙坦的口服生物利用度。
Drug Des Devel Ther. 2015 May 22;9:2745-56. doi: 10.2147/DDDT.S84070. eCollection 2015.
10
Solid-nanoemulsion preconcentrate for oral delivery of paclitaxel: formulation design, biodistribution, and γ scintigraphy imaging.用于紫杉醇口服给药的固体纳米乳预浓缩物:制剂设计、生物分布及γ闪烁成像
Biomed Res Int. 2014;2014:984756. doi: 10.1155/2014/984756. Epub 2014 Jul 14.
瑞格列奈二元脂质基质固体脂质纳米粒的研究:体外与体内评价。
J Pharm Sci. 2011 Jun;100(6):2366-78. doi: 10.1002/jps.22435. Epub 2011 Jan 5.
4
Development of valsartan-loaded gelatin microcapsule without crystal change using hydroxypropylmethylcellulose as a stabilizer.采用羟丙甲纤维素作为稳定剂制备载缬沙坦明胶微胶囊且无晶体变化。
Drug Deliv. 2010 Jul;17(5):322-9. doi: 10.3109/10717541003717031.
5
Preparation and bioavailability assessment of SMEDDS containing valsartan.含缬沙坦的 SMEDDS 的制备及生物利用度评价。
AAPS PharmSciTech. 2010 Mar;11(1):314-21. doi: 10.1208/s12249-010-9385-0. Epub 2010 Feb 25.
6
Solid self-emulsifying nitrendipine pellets: preparation and in vitro/in vivo evaluation.固体自乳化硝苯地平微丸:制备及体外/体内评价。
Int J Pharm. 2010 Jan 4;383(1-2):1-6. doi: 10.1016/j.ijpharm.2009.08.014. Epub 2009 Aug 19.
7
Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems.自乳化药物递送系统提高辅酶Q10的口服生物利用度。
Int J Pharm. 2009 Jun 5;374(1-2):66-72. doi: 10.1016/j.ijpharm.2009.03.008. Epub 2009 Mar 19.
8
Formulation and in vitro and in vivo characterization of a phenytoin self-emulsifying drug delivery system (SEDDS).苯妥英钠自乳化药物递送系统(SEDDS)的制剂及其体外和体内特性研究
Eur J Pharm Sci. 2008 Nov 15;35(4):257-63. doi: 10.1016/j.ejps.2008.07.004. Epub 2008 Jul 25.
9
A new solid self-microemulsifying formulation prepared by spray-drying to improve the oral bioavailability of poorly water soluble drugs.一种通过喷雾干燥制备的新型固体自微乳化制剂,用于提高难溶性药物的口服生物利用度。
Eur J Pharm Biopharm. 2008 Oct;70(2):439-44. doi: 10.1016/j.ejpb.2008.05.001. Epub 2008 May 17.
10
Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms.固体自乳化药物递送系统的研发:制备技术与剂型
Drug Discov Today. 2008 Jul;13(13-14):606-12. doi: 10.1016/j.drudis.2008.04.006. Epub 2008 Jun 3.